WT1: a weak spot in KRAS-induced transformation.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Activating Ras mutations are common in tumors, but Ras proteins are difficult direct therapeutic targets.
• Synthetic lethality screens identify genes whose simultaneous silencing with a specific mutation is incompatible with cell survival.
• Identifying indirect targets is a key strategy to inhibit Ras-driven oncogenesis.

Purpose of the Study:

• To identify genes that exhibit synthetic lethality with activating Kras mutations in a mouse model of lung adenocarcinoma.
• To investigate the therapeutic potential of targeting Kras synthetic-lethal genes.

Main Methods:

• Utilized RNAi-based negative selection screens to identify synthetic-lethal interactions.
• Developed a mouse model of lung adenocarcinoma with an endogenous activated Kras allele.
• Assessed the impact of Wilms tumor 1 (Wt1) silencing on cancer cell proliferation and tumor progression in vitro and in vivo.

Main Results:

• Identified Wilms tumor 1 (Wt1) as a Kras synthetic-lethal gene.
• Silencing of Wt1 in cells with activated Kras triggered senescence in vitro.
• Wt1 silencing demonstrated an impact on tumor progression in vivo.

Conclusions:

• Wilms tumor 1 (Wt1) is a Kras synthetic-lethal gene with potential as a therapeutic target in Kras-driven lung adenocarcinoma.
• Targeting Wt1 may offer a novel strategy to inhibit oncogenesis driven by activating Kras mutations.
• Findings contribute to understanding the context-dependent role of oncogenic Kras in senescence versus proliferation.